Literature DB >> 22948894

A perspective on efflux transport proteins in the liver.

K Köck1, K L R Brouwer.   

Abstract

Detailed knowledge regarding the influence of hepatic transport proteins on drug disposition has advanced at a rapid pace over the past decade. Efflux transport proteins located in the basolateral and apical (canalicular) membranes of hepatocytes play an important role in the hepatic elimination of many endogenous and exogenous compounds, including drugs and metabolites. This review focuses on the role of these efflux transporters in hepatic drug excretion. The impact of these proteins as underlying factors for disease is highlighted, and the importance of hepatic efflux proteins in the efficacy and toxicity of drugs is discussed. In addition, a brief overview of methodology to evaluate the function of hepatic efflux transport proteins is provided. Current challenges in predicting the impact of altered efflux protein function on systemic, intestinal, and hepatocyte exposure to drugs and metabolites are highlighted.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22948894      PMCID: PMC3725336          DOI: 10.1038/clpt.2012.79

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  129 in total

1.  Systematic screening of human ABCC3 polymorphisms and their effects on MRP3 expression and function.

Authors:  Tomohiro Sasaki; Takeshi Hirota; Yuriko Ryokai; Daisuke Kobayashi; Miyuki Kimura; Shin Irie; Shun Higuchi; Ichiro Ieiri
Journal:  Drug Metab Pharmacokinet       Date:  2011-04-22       Impact factor: 3.614

Review 2.  Systematic review of benefits and risks of second-line irinotecan monotherapy for advanced colorectal cancer.

Authors:  Linda J M Oostendorp; Peep F Stalmeier; Pieternel C Pasker-de Jong; Winette T Van der Graaf; Petronella B Ottevanger
Journal:  Anticancer Drugs       Date:  2010-09       Impact factor: 2.248

Review 3.  Membrane transporters in drug development.

Authors:  Kathleen M Giacomini; Shiew-Mei Huang; Donald J Tweedie; Leslie Z Benet; Kim L R Brouwer; Xiaoyan Chu; Amber Dahlin; Raymond Evers; Volker Fischer; Kathleen M Hillgren; Keith A Hoffmaster; Toshihisa Ishikawa; Dietrich Keppler; Richard B Kim; Caroline A Lee; Mikko Niemi; Joseph W Polli; Yuichi Sugiyama; Peter W Swaan; Joseph A Ware; Stephen H Wright; Sook Wah Yee; Maciej J Zamek-Gliszczynski; Lei Zhang
Journal:  Nat Rev Drug Discov       Date:  2010-03       Impact factor: 84.694

4.  Two-photon laser scanning fluorescence microscopy.

Authors:  W Denk; J H Strickler; W W Webb
Journal:  Science       Date:  1990-04-06       Impact factor: 47.728

5.  Hepatocanalicular bile salt export pump deficiency in patients with progressive familial intrahepatic cholestasis.

Authors:  P L Jansen; S S Strautnieks; E Jacquemin; M Hadchouel; E M Sokal; G J Hooiveld; J H Koning; A De Jager-Krikken; F Kuipers; F Stellaard; C M Bijleveld; A Gouw; H Van Goor; R J Thompson; M Müller
Journal:  Gastroenterology       Date:  1999-12       Impact factor: 22.682

6.  Troglitazone-induced intrahepatic cholestasis by an interference with the hepatobiliary export of bile acids in male and female rats. Correlation with the gender difference in troglitazone sulfate formation and the inhibition of the canalicular bile salt export pump (Bsep) by troglitazone and troglitazone sulfate.

Authors:  C Funk; M Pantze; L Jehle; C Ponelle; G Scheuermann; M Lazendic; R Gasser
Journal:  Toxicology       Date:  2001-10-05       Impact factor: 4.221

7.  Genetic susceptibility to diclofenac-induced hepatotoxicity: contribution of UGT2B7, CYP2C8, and ABCC2 genotypes.

Authors:  Ann K Daly; Guruprasad P Aithal; Julian B S Leathart; Richard A Swainsbury; Tarana Singh Dang; Christopher P Day
Journal:  Gastroenterology       Date:  2006-11-17       Impact factor: 22.682

8.  Enterohepatic circulation of indomethacin and its role in intestinal irritation.

Authors:  D E Duggan; K F Hooke; R M Noll; K C Kwan
Journal:  Biochem Pharmacol       Date:  1975-10-01       Impact factor: 5.858

Review 9.  Multidrug resistance proteins (MRPs, ABCCs): importance for pathophysiology and drug therapy.

Authors:  Dietrich Keppler
Journal:  Handb Exp Pharmacol       Date:  2011

10.  Canalicular multispecific organic anion transporter/multidrug resistance protein 2 mediates low-affinity transport of reduced glutathione.

Authors:  C C Paulusma; M A van Geer; R Evers; M Heijn; R Ottenhoff; P Borst; R P Oude Elferink
Journal:  Biochem J       Date:  1999-03-01       Impact factor: 3.857

View more
  24 in total

1.  Altered morphine glucuronide and bile acid disposition in patients with nonalcoholic steatohepatitis.

Authors:  B C Ferslew; C K Johnston; E Tsakalozou; A S Bridges; M F Paine; W Jia; P W Stewart; A S Barritt; K L R Brouwer
Journal:  Clin Pharmacol Ther       Date:  2015-03-15       Impact factor: 6.875

2.  Novel Mechanisms of Valproate Hepatotoxicity: Impaired Mrp2 Trafficking and Hepatocyte Depolarization.

Authors:  Dong Fu; Panli Cardona; Henry Ho; Paul B Watkins; Kim L R Brouwer
Journal:  Toxicol Sci       Date:  2019-07-31       Impact factor: 4.849

3.  Role of multidrug resistance-associated protein 4 in the basolateral efflux of hepatically derived enalaprilat.

Authors:  Brian C Ferslew; Kathleen Köck; Arlene S Bridges; Kim L R Brouwer
Journal:  Drug Metab Dispos       Date:  2014-06-23       Impact factor: 3.922

Review 4.  Transporters in Drug Development: 2018 ITC Recommendations for Transporters of Emerging Clinical Importance.

Authors:  Maciej J Zamek-Gliszczynski; Mitchell E Taub; Paresh P Chothe; Xiaoyan Chu; Kathleen M Giacomini; Richard B Kim; Adrian S Ray; Sophie L Stocker; Jashvant D Unadkat; Matthias B Wittwer; Cindy Xia; Sook-Wah Yee; Lei Zhang; Yan Zhang
Journal:  Clin Pharmacol Ther       Date:  2018-08-08       Impact factor: 6.875

Review 5.  Prediction of pharmacokinetics and drug-drug interactions when hepatic transporters are involved.

Authors:  Rui Li; Hugh A Barton; Manthena V Varma
Journal:  Clin Pharmacokinet       Date:  2014-08       Impact factor: 6.447

6.  Relevance of Liver Failure for Anti-Infective Agents: From Pharmacokinetic Alterations to Dosage Adjustments.

Authors:  Fiona V Bϋdingen; Daniel Gonzalez; Amelia N Tucker; Hartmut Derendorf
Journal:  Ther Adv Infect Dis       Date:  2014-02-01

7.  A metabolomic perspective of griseofulvin-induced liver injury in mice.

Authors:  Ke Liu; Jiong Yan; Madhav Sachar; Xinju Zhang; Ming Guan; Wen Xie; Xiaochao Ma
Journal:  Biochem Pharmacol       Date:  2015-09-05       Impact factor: 5.858

8.  Gene-by-Environment Interaction of Bcrp-/- and Methionine- and Choline-Deficient Diet-Induced Nonalcoholic Steatohepatitis Alters SN-38 Disposition.

Authors:  Erica L Toth; Hui Li; Anika L Dzierlenga; John D Clarke; Anna Vildhede; Michael Goedken; Nathan J Cherrington
Journal:  Drug Metab Dispos       Date:  2018-08-30       Impact factor: 3.922

9.  High-Fidelity Drug-Induced Liver Injury Screen Using Human Pluripotent Stem Cell-Derived Organoids.

Authors:  Tadahiro Shinozawa; Masaki Kimura; Yuqi Cai; Norikazu Saiki; Yosuke Yoneyama; Rie Ouchi; Hiroyuki Koike; Mari Maezawa; Ran-Ran Zhang; Andrew Dunn; Autumn Ferguson; Shodai Togo; Kyle Lewis; Wendy L Thompson; Akihiro Asai; Takanori Takebe
Journal:  Gastroenterology       Date:  2020-10-08       Impact factor: 22.682

10.  Transporter-Mediated Alterations in Patients With NASH Increase Systemic and Hepatic Exposure to an OATP and MRP2 Substrate.

Authors:  Izna Ali; Jason R Slizgi; Josh D Kaullen; Marija Ivanovic; Mikko Niemi; Paul W Stewart; Alfred S Barritt; Kim L R Brouwer
Journal:  Clin Pharmacol Ther       Date:  2017-12-22       Impact factor: 6.875

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.